197 related articles for article (PubMed ID: 8481830)
1. Serum levels of bone Gla protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegaly: effects of long-term octreotide treatment.
Terzolo M; Piovesan A; Osella G; Pia A; Reimondo G; Pozzi C; Raucci C; Torta M; Paccotti P; Angeli A
Calcif Tissue Int; 1993 Mar; 52(3):188-91. PubMed ID: 8481830
[TBL] [Abstract][Full Text] [Related]
2. Biochemical markers of bone and collagen turnover in acromegaly or Cushing's syndrome.
Piovesan A; Terzolo M; Reimondo G; Pia A; Codegone A; Osella G; Boccuzzi A; Paccotti P; Angeli A
Horm Metab Res; 1994 May; 26(5):234-7. PubMed ID: 8076906
[TBL] [Abstract][Full Text] [Related]
3. Effects of a growth hormone receptor antagonist on bone markers in acromegaly.
Fairfield WP; Sesmilo G; Katznelson L; Pulaski K; Freda PU; Stavrou S; Kleinberg D; Klibanski A
Clin Endocrinol (Oxf); 2002 Sep; 57(3):385-90. PubMed ID: 12201832
[TBL] [Abstract][Full Text] [Related]
4. Serum osteocalcin and carboxyterminal propeptide of type I procollagen in rheumatoid arthritis.
Kröger H; Risteli J; Risteli L; Penttilä I; Alhava E
Ann Rheum Dis; 1993 May; 52(5):338-42. PubMed ID: 8323381
[TBL] [Abstract][Full Text] [Related]
5. Twenty-four-hour osteocalcin, carboxyterminal propeptide of type I procollagen, and aminoterminal propeptide of type III procollagen rhythms in normal and growth-retarded children.
Saggese G; Baroncelli GI; Bertelloni S; Cinquanta L; DiNero G
Pediatr Res; 1994 Apr; 35(4 Pt 1):409-15. PubMed ID: 8047377
[TBL] [Abstract][Full Text] [Related]
6. Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly.
Salmela PI; Juustila H; Pyhtinen J; Jokinen K; Alavaikko M; Ruokonen A
J Clin Endocrinol Metab; 1990 Apr; 70(4):1193-201. PubMed ID: 2180976
[TBL] [Abstract][Full Text] [Related]
7. Skeletal involvement in female acromegalic subjects: the effects of growth hormone excess in amenorrheal and menstruating patients.
Scillitani A; Chiodini I; Carnevale V; Giannatempo GM; Frusciante V; Villella M; Pileri M; Guglielmi G; Di Giorgio A; Modoni S; Fusilli S; Di Cerbo A; Liuzzi A
J Bone Miner Res; 1997 Oct; 12(10):1729-36. PubMed ID: 9333135
[TBL] [Abstract][Full Text] [Related]
8. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human insulin-like growth factor I, recombinant human growth hormone, and sex steroids: effects on markers of bone turnover in humans.
Mauras N; Doi SQ; Shapiro JR
J Clin Endocrinol Metab; 1996 Jun; 81(6):2222-6. PubMed ID: 8964855
[TBL] [Abstract][Full Text] [Related]
10. Increased serum levels of carboxyterminal propeptide of type 1 collagen (PICP) in hyperthyroidism.
Legovini P; De Menis E; Da Rin G; Roiter I; Breda F; Artuso V; Di Virgilio R; Conte N
Horm Metab Res; 1994 Jul; 26(7):334-7. PubMed ID: 7959610
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor-I raises serum procollagen levels in children and adults with Laron syndrome.
Klinger B; Jensen LT; Silbergeld A; Laron Z
Clin Endocrinol (Oxf); 1996 Oct; 45(4):423-9. PubMed ID: 8959080
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
Ho KY; Weissberger AJ; Marbach P; Lazarus L
Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
[TBL] [Abstract][Full Text] [Related]
13. Type I procollagen propeptide in patients on CAPD: its relationships with bone histology, osteocalcin, and parathyroid hormone.
Joffe P; Heaf JG; Jensen LT
Nephrol Dial Transplant; 1995 Oct; 10(10):1912-7. PubMed ID: 8592603
[TBL] [Abstract][Full Text] [Related]
14. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.
Invitti C; Fatti L; Camboni MG; Porcu L; Danesi L; Delitala G; Cavagnini F
J Endocrinol Invest; 1996 Sep; 19(8):548-55. PubMed ID: 8905479
[TBL] [Abstract][Full Text] [Related]
15. Serum type III procollagen propeptide levels in acromegalic patients.
Verde GG; Santi I; Chiodini P; Cozzi R; Dallabonzana D; Oppizzi G; Liuzzi A
J Clin Endocrinol Metab; 1986 Dec; 63(6):1406-10. PubMed ID: 2878008
[TBL] [Abstract][Full Text] [Related]
16. Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major.
Sartorio A; Conte G; Conti A; Masala A; Alagna S; Rovasio P; Faglia G
J Endocrinol Invest; 2000 Jun; 23(6):356-61. PubMed ID: 10908162
[TBL] [Abstract][Full Text] [Related]
17. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
Hunter SJ; Shaw JA; Lee KO; Wood PJ; Atkinson AB; Bevan JS
Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369
[TBL] [Abstract][Full Text] [Related]
18. The pulsatile GH secretion in acromegaly: hypothalamic or pituitary origin?
Riedel M; Günther T; von zur Mühlen A; Brabant G
Clin Endocrinol (Oxf); 1992 Sep; 37(3):233-9. PubMed ID: 1358484
[TBL] [Abstract][Full Text] [Related]
19. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases.
Francini G; Gonnelli S; Petrioli R; Bruni S; Marsili S; Aquino A; Camporeale A
Cancer Epidemiol Biomarkers Prev; 1993; 2(2):125-9. PubMed ID: 8467247
[TBL] [Abstract][Full Text] [Related]
20. The association between insulin-like growth factor 1 (IGF-1), IGF-binding proteins (IGFBPs), and the carboxyterminal propeptide of type I procollagen (PICP) in pre- and postmenopausal women with rheumatoid arthritis.
Szeremeta A; Jura-Półtorak A; Komosińska-Vassev K; Zoń-Giebel A; Kapołka D; Olczyk K
Scand J Rheumatol; 2017 May; 46(3):171-179. PubMed ID: 27775453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
